Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL).
